Coccidioidomycosis medical therapy
|
Coccidioidomycosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Coccidioidomycosis medical therapy On the Web |
|
American Roentgen Ray Society Images of Coccidioidomycosis medical therapy |
|
Risk calculators and risk factors for Coccidioidomycosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: ; Vidit Bhargava, M.B.B.S [2]
Treatment
The drug therapy is guided by the severity of symptoms and the immune status of the patient. Since most patients are asymptomatic or mildly affected, no treatment or a single drug Azole therapy (fluconazole or itraconazole) may be sufficient in these cases.However patients with HIV, immune-compromised, those on steroids or pregnant females need much more aggressive approach.More recently resistant cases are being treated with voriconazole or posaconazole.[1]. More severe cases may require intravenous Amphotericin B, with or without simultaneous oral azole therapy. Pregnant females are treated by Intravenous amphotericin B only.
Severe cases like meningitis or vasculitis often need initial in-patient treatment with oral azoles plus intravenous amphotericin B with or without intrathecal amphotericin B. Untreated cases may sometimes be fatal.
References
- ↑ Chen, S.; Erhart, LM.; Anderson, S.; Komatsu, K.; Park, B.; Chiller, T.; Sunenshine, R. (2011). "Coccidioidomycosis: knowledge, attitudes, and practices among healthcare providers--Arizona, 2007". Med Mycol. 49 (6): 649–56. doi:10.3109/13693786.2010.547995. PMID 21247229. Unknown parameter
|month=ignored (help)